INTRODUCTION
The numbers of serious fungal infections continue to rise, particularly in patients who become severely immunosuppressed as a result of therapy for cancers, organ transplant or bone marrow transplant. These patients are at higher risk of developing aspergillosis, which can be a devastating disease, with mortalities approaching 50 % overall (higher in some patients groups) in spite of antifungal therapy (Dasbach et al., 2000; Stevens, 2000; Marr et al., 2002; Steinbach & Stevens, 2003; Cassone & Torosantucci, 2006; Warnock, 2006) . Furthermore, the rise in resistance to antifungal therapies makes control of this disease ever more difficult.
Prevention of infection with Aspergillus fumigatus through the use of a vaccine is a highly desirable option, given the near 50 % mortality rate even of patients on optimal therapy (Herbrecht et al., 2002) . The rationale for vaccinating patients at risk, such as those undergoing stem cell transplants or solid organ transplants who could be vaccinated prior to the initial immunosuppressive therapy, or the possibility of vaccinating the donor prior to a bone marrow transplant, has been discussed previously (Stevens, 2004) . However, there are no licensed antifungal vaccines currently available. Numerous investigations have examined various antigenic preparations including specific proteins, carbohydrate moieties and conjugate vaccines (Cenci et al., 2000; Bozza et al., 2002; Ito & Lyons, 2002 Stevens et al., 2011; Liu et al., 2011a) . We have reported previously that heat-killed yeasts of Saccharomyces cerevisiae (HKY) given subcutaneously are protective against fungi from five genera, including A. fumigatus (Capilla et al., 2009; Stevens et al., 2011; Liu et al., 2011a Liu et al., , 2012a Luo et al., 2014; Majumder et al., 2014) . These results are indicative of the potential of developing a more highly effective pan-fungal vaccine, with HKY as the prototype. As part of our ongoing studies to determine the protective components of the HKY we have also shown that protein-glycan conjugates containing mannans or glucans can induce a protective response against A. fumigatus and Coccidioides posadasii (Liu et al., 2010 (Liu et al., , 2012b Stevens et al., 2011) . Similarly, previous studies used a laminarin-diphtheria toxoid conjugate and demonstrated protection against several fungi (Torosantucci et al., 2005 (Torosantucci et al., , 2009 ). These studies further support the potential of developing a pan-fungal vaccine.
We report here the results of studies using highly purified bglucans, either soluble or particulate, alone or as a conjugate with a non-specific protein, BSA, as vaccine preparations against experimental systemic aspergillosis. Our results demonstrate that the particulate glucan alone or as a conjugate, but not the soluble glucan or its conjugate, provide significant prolongation of survival and serve as a proof of principle for the utility of a glycan-protein antifungal vaccine.
METHODS
Vaccine preparations. An HKY vaccine preparation was used for the positive control. HKY vaccine was made as described previously (Capilla et al., 2009; Liu et al., 2011a Liu et al., , 2011b ) and kept at 4 uC. Briefly, S. cerevisiae strain 96-108 was cultured in yeast extract peptone glucose (YPD) broth on an orbital shaker at 37 uC for 24 h. Cells were pelleted and washed by centrifugation three times with PBS (pH 7.0). Cells were suspended in PBS and heat-killed at 70 uC for 3 h. Viability was tested by plating on Sabouraud dextrose agar (SDA) for 5 days. HKY was adjusted to 4610 8 cells ml 21 by haemocytometer counting.
S. cerevisiae-derived whole glucan particles (WGP) and soluble medium molecular mass (MMW) b-glucan were prepared and (Bailey, 1958) . DDetection of %N by combustion analysis and multiplication by 6.25. dHydrolysis with trifluoroacetic acid to monosaccharides followed by high performance anion-exchange chromatography with pulsed amperometric detection. §Digestion by amyloglucosidase and detection of liberated glucose by an enzymatic glucose detection assay. ||Hydrolysis with sulfuric acid followed by reaction with acetyl acetone and Ehrlich's reagent and detection spectrophotometrically. GEM b-glucan assay (Danielson et al., 2010) . # Partially methylated alditol acetate method using GC with flameionization detection (York et al., 1985) . **Measurement by microscopy. 
characterized by Biothera (Eagan). WGP was purified from S. cerevisiae through a series of alkaline and acid extractions as previously described (Manners et al., 1973) , with the exceptions that sulfuric acid was substituted for acetic acid and the final WGP suspension was sonicated prior to use; soluble MMW b-glucan was prepared by acid hydrolysis of WGPs (Magee et al., 2007) followed by preparative gel permeation chromatography (GPC) to yield a soluble glucan with a average molecular mass of 150 kDa (Manners et al., 1973; Hong et al., 2004; Yan et al., 2005; Tian et al., 2012) . Because the WGP preparations proved effective, they were characterized in detail (Bailey, 1958; York et al., 1985; Danielson et al., 2010) , see Table 1 .
The BSA conjugation was done using two different methods. Briefly, the first method involved treating either WGP or MMW glucan with sodium periodate, resulting in the formation of aldehydes on the nonreducing glucose residues of the side chains and main chain termini. Reductive amination of the oxidized glucan with BSA was accomplished by first heating the mixture overnight at 50 uC and then adding sodium cyanoborohydride and heating the mixture overnight at the same temperature (Ahmad et al., 2006) . These preparations are characterized in Table 2 . The second method was done using a 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated conjugation (Bystrický et al., 2000) ; these preparations are characterized in Table 3 . The reaction mixtures obtained from both methods were quenched with ethanolamine. The WGP-BSA conjugate pellets were washed by centrifugation with PBS and the soluble MMW-BSA conjugates were washed with PBS by 10 kDa diafiltration. All preparations were tested for endotoxin content (PyroGene Endotoxin assay fluorescent detection; Lonza) and all preparations, conjugated and unconjugated WGP or MMW glucan, had ,0.1 unit of endotoxin present. Cultures on media for fungi or bacteria showed sterility of the preparations. The proportion of glucan in the conjugates was measured by a colorimetric hexose assay (Bailey, 1958) and the amount of BSA was determined by measuring the weight percent of nitrogen (%N) in the conjugate by combustion analysis and multiplication by a protein factor of 6.25. The conjugates were expressed as the weight of the total, not the carbohydrate alone. The average molecular mass of the starting soluble MMW glucan and the soluble MMW-BSA conjugates was determined by GPC with detection by differential refractive index and multi-angle light scattering. Tables 2 and 3 list the ratio of the glucan to BSA in the conjugates and the average molecular mass of the soluble preparations.
Mice. Five-week-old male CD-1 mice (Charles River Laboratories) were used. Animals were housed under conventional conditions with five in each cage. Experimental groups consisted of 10 mice. All animals were used under a protocol approved by the Institutional Animal Care and Use Committee of the California Institute for Medical Research. Animal husbandry was done using the guidelines of the Office of Laboratory Animal Welfare of the National Institute of Health and the Guide for the Care and use of Laboratory Animals, eighth edition.
Vaccination. Two separate studies were performed. Vaccines were administered subcutaneously to non-immunosuppresed mice using two dorsal sites (i.e. 0.15 ml each site for glucan antigen candidate; 0.075 ml each for PBS or HKY control at each site) on a schedule of day 28, 21 and 14 before challenge (Liu et al., 2011a) . HKY [6610 7 yeast per dose (equivalent to 2.5 mg)] was used as a positive control vaccine and PBS alone was the negative control. The vaccine preparations and the dosages used in these studies are listed in Tables 2 and 3 .
Infection. Mice were infected with A. fumigatus strain 10AF conidia. Conidia were harvested in saline with Tween 80 (0.05 %, v/v) from sporulated cultures grown for 5 to 7 days on potato dextrose agar at 37 uC as previously described (Denning & Stevens, 1991; Hanson et al., 1995; Luque et al., 2003; Liu et al., 2011a) . The viability of the inoculum was determined by plating 10-fold dilutions of conidia onto SDA plates, as well as enumeration by haemocytometer counting to prepare an inoculum for infection. In the initial study, each mouse received 7.45610 6 viable conidia in saline/Tween 80 and in the second study each mouse received 9.8610 6 conidia. To initiate the systemic model of infection, 0.25 ml conidial suspension was inoculated intravenously via a lateral tail vein.
Survival and tissue burdens. All mice were checked for survival daily. Sixteen days after infection, surviving mice were euthanized by CO 2 anoxia. The c.f.u. remaining in the organs was determined by quantitative plating of organ homogenates as previously described (Denning & Stevens, 1991; Hanson, Clemons et al., 1995; Luque et al., 2003) . In brief, the brain and kidneys were removed aseptically, homogenized in 0.9 % saline containing 100 IU penicillin and 100 mg streptomycin ml 21 and serially diluted. Samples of 10-fold dilutions were plated onto SDA containing 50 mg chloramphenicol per litre and incubated for 2 days at ambient temperature; c.f.u. were counted and the log 10 c.f.u. per organ was determined.
Immunological studies. A separate study was performed to evaluate the immunological response of the mice to vaccination with WGP or WGP-BSA. Groups of five mice were vaccinated on the three-dose schedule as described above with 6 mg WGP or WGP-BSA, or 0.06 mg WGP, or PBS. Two weeks after the last vaccine dose, samples were collected from each mouse. Mice were exsanguinated under isoflurane anaesthesia by severing the brachial artery and blood was collected for serum. Bronchoalveolar lavage (BAL) fluid was collected as previously described (Sugar et al., 1983; Liu et al., 2011b) and 2 ml PBS lavage fluid was collected from each mouse. Samples were stored frozen at 280 uC until used for assays.
Cytokine measurement was done on serum and BAL using a 22-plex assay by Luminex multi-analyte XMAP profiling technology (Life Technologies). Anti-b-glucan antibody levels in serum were measured following incubation of the samples with b-glucan-coated beads and an anti-mouse IgG-PE (phycoerythrin) or IgM-APC (allophycocyanin) specific secondary detection antibody. The bead-based flow assay is based on Cytometric Bead Assay technology (CBA Human Th1/ Th2/Th17; BD Biosciences). Briefly, b-1,3/1,6-glucan was coated onto 10 mm polystyrene beads (catalogue no. 17136; Polysciences) using a photoactivatable cross-linker. Mouse serum samples were diluted in PBS containing 0.1 % BSA and incubated with b-glucan-coated beads for 1.5 h at room temperature. The beads were washed twice in PBS and incubated with anti-mouse IgM-APC (Jackson ImmunoResearch Laboratories) and anti-mouse IgG-PE (Biolegend) antibodies for 30 min at room temperature. Following incubation, the beads were washed with PBS and analysed on a BD LSRII flow cytometer. Median fluorescent intensity was determined for both IgG and IgM and mass units (ng ml 21 ) were determined for each sample by extrapolation Statistical evaluation. Statistical comparison of survival was done by a log rank test and comparison of c.f.u. burdens using the MannWhitney U-test. For c.f.u. comparisons, data points missing due to the death of the animal from infection were assigned an arbitrary log 10 value of 5 and included in the statistical comparisons (Lachin, 1999; Shih, 2002) . This assignment assures that death due to infection is a worse outcome than is survival regardless of fungal burden.
RESULTS
Initial studies with b-glucan
In our initial study, we examined soluble and particulate preparations of b-glucan with or without conjugation to BSA. It should be noted that one mouse from the group of 0.6 mg MMW glucan, and two mice each from groups of 0.6 mg or 6 mg MMW-BSA died after vaccination and before challenge with A. fumigatus 10AF, but the cause of death could not be attributed to a specific cause; there was no apparent dose responsiveness and these animals were excluded from additional analyses.
After 16 days of infection, compared to the PBS controls that died from days 3 to 8, the HKY positive control had prolonged survival and 70 % of the mice survived (P,0.0001; Fig. 1 ). Vaccination with unconjugated or conjugated soluble glucan (MMW glucan or MMW-BSA) at any dose did not result in significant protective efficacy (Fig. 1a, b) . This was confirmed in a separate study of doses of up to 12 mg MMW glucan (data not shown). However, administration of 0.6, 6 or 12 mg insoluble WGP regimens prolonged survival compared to the PBS control group (all P,0.005; Fig. 1c ). Vaccination with 6 or 12 mg BSA-conjugated insoluble WGP in regimens showed significant protective efficacy (P,0.0001, P50.0002, respectively; Fig. 1d ), but not 0.6 mg. HKY was superior to all doses of unconjugated or conjugated soluble glucan (MMW glucan or MMW-BSA, P,0.0001 to 0.0016, depending on comparison), but was equivalent to all doses of unconjugated WGP and the 6 or 12 mg WGP-BSA regimens (P.0.05); HKY was superior to 0.6 mg WGP-BSA (P50.0002). All three dose regimens of WGP were superior to equivalent doses of soluble MMW glucan in prolonging mouse survival (all P,0.002) and to all doses of MMW-BSA (P,0.02-0.002, depending on comparison). A dose of 0.6 mg WGP was superior to 0.6 mg WGP-BSA, whereas 6 or 12 mg WGP-BSA was not significantly different from the equivalent doses of WGP.
The residual fungal burden was determined in surviving mice in the kidneys and brain. Overall, these results paralleled those of the survival. HKY vaccination was superior to PBS, MMW glucan or MMW-BSA, and WGP-BSA at 0.6 mg in reduction of c.f.u. from the brain (P ¡0.02 to 0.004, dependent on comparison) and kidney (P ¡0.05 to 0.004, dependent on comparison), but equivalent to all doses of WGP glucan and the 6 or 12 mg WGP-BSA doses (data not shown). Notably, two mice vaccinated with 12 mg WGP-BSA were free of detectable infection, whereas all other vaccinated animals were infected in one or both organs.
Second study
To validate the results of the initial study we performed a second study with preparations that induced significant protection. Our design for this experiment included the same dosages of WGP or WGP-BSA that had proven efficacious in the first study and also one lower dosage. We also included a maximal dosage of MMW glucan or MMW-BSA to determine whether the lack of protection may have been due to insufficient antigen stimulation.
Mice were vaccinated and infected as before and followed for survival through 16 days of infection. The infection resulted in high mortality, with 100 % of PBS control mice succumbing to infection by day 9. The positive vaccine control, HKY, proved effective with 70 % survival (Fig. 2) . Soluble MMW glucan either alone or as a BSA conjugate was ineffective, both groups having 100 % mortality. Thus, the soluble MMW glucan (even at 24 mg soluble MMW glucan) was ineffective as a vaccine, similar to the results with a dosage of 12 mg soluble MMW glucan used in the initial studies. The use of WGP alone or as a BSA conjugate proved more effective, with up to 80 % survival depending on the dose and conjugation (Fig. 2) . In comparison to PBS, 12, 6 and 0.6 mg WGP-BSA doses, as well as 12 or 6 mg WGP alone, induced significant protection against systemic aspergillosis (P¡0.014, dependent on comparison); 0.06 mg WGP-BSA and 0.6 or 0.06 mg WGP were ineffective (Fig. 2) . No effective WGP-BSA or WGP dosage was superior to HKY. In addition, BSA conjugation of WGP did not provide significantly enhanced protection over the non-conjugated WGP. Some dose responsiveness was noted in that the 12 or 6 mg WGP doses were superior to the 0.6 or 0.006 mg WGP doses (P¡0.017, dependent on comparison). Overall, these results were similar to those of the initial study, with the exception that 0.6 mg WGP-BSA showed significant protection in the second study.
It is of interest to note that in the second experiment, as well as in the previous study, the conjugation of BSA to WGP did not significantly enhance the activity of WGP. However, in the second study 0.6 mg WGP-BSA showed significant protective effects, while WGP did not, and although these regimens were not significantly different, these results may be suggestive of potential enhancement of the WGP by conjugation to BSA.
The results of the recovery of c.f.u. from the brain and kidneys of surviving mice were similar to those of the initial study. For both organs, only mice vaccinated with HKY, WGP-BSA and WGP at 6 or 12 mg had significantly fewer c.f.u. than PBS-treated (P,0.04 to 0.001, dependent on comparison; Fig. 3 ). Each of these regimens was equivalent and BSA conjugation of WGP did not improve the efficacy of the WGP alone. Unlike the survival results, 0.6 mg WGP-BSA was not significantly effective. Minimal dose responsiveness was observed with 6 or 12 mg WGP-BSA superior to lower doses; all doses of WGP alone were equivalent in the brain and 6 or 12 mg WGP was superior to lower doses of WGP alone in the kidneys. No dose of WGP-BSA or WGP was superior to HKY; unlike the initial study where two mice vaccinated with 12 mg WGP-BSA were free of detectable infection, no animals in the repeat study cleared the infection in both organs.
Cytokines and anti-b-glucan antibodies in vaccinated mice
CD-1 mice (five mice per group) were vaccinated as described, with vehicle (PBS), WGP (6 mg or 0.06 mg) or WGP-BSA (6 mg). Two weeks after the last doses, serum and BAL fluid were collected for cytokine analyses using a 22-plex Luminex assay. Of the 22 soluble factors analysed, WGP vaccination that was administered in vivo upregu- (Table 4) . The profile suggests activation of both innate and adaptive immune cells.
Evaluation of the serum from these vaccinated mice for anti-b-glucan antibody levels showed no or minimal increases in specific IgM or IgG antibodies (Fig. 4) , suggesting that antibodies may be involved only minimally in mediating the observed protective response. 
DISCUSSION
In our work over the last several years we have addressed the possibility of developing a pan-fungal vaccine, demonstrating that killed yeast of Saccharomyces induces an immune response, as well as protection against several fungal infections (Capilla et al., 2009; Liu et al., 2011a Liu et al., ,b, 2012a Luo et al., 2014; Majumder et al., 2014) . Although the antigens inducing protection remain unknown, we postulated that glycans may be responsible in part for the induced protection and demonstrated that partially purified mannan or b-glucan alone, or conjugated to BSA, could induce an immune response sufficient to protect mice against lethal infection (Liu et al., 2010 (Liu et al., , 2012b Stevens et al., 2011) . Furthermore, we found that higher molecular mass mannan induced a superior protective response when administered alone and that conjugation of the mannan with BSA enhanced the response significantly (Liu et al., 2012b) .
In our current studies, we have examined the use of different forms of highly purified b-glucan. Torosantucci et al. (2005) used a soluble linear form of b-glucan, laminarin, which was conjugated to the diphtheria protein toxoid and showed it was efficacious in protecting against different experimental fungal infections. Those authors linked the induction of antibodies directed at b-1,3-glucan to the mechanism of protection (Torosantucci et al., 2009 ). In the current studies, we used a soluble or particulate form of b-glucan derived from S. cerevisiae, and used BSA as the protein for conjugation. Interestingly, the soluble form of b-glucan alone or conjugated to BSA was not protective, which is unlike the previous results (Torosantucci et al., 2005 (Torosantucci et al., , 2009 ). Similar to our previous studies using other particulates (Stevens et al., 2011) , the particulate WGP or WGP-BSA form was very effective, inducing significant protective response against systemic aspergillosis. It should be noted that conjugation methodology did not alter the effectiveness of the WGP-BSA. Furthermore, the protection induced by these preparations was equivalent or slightly better than that which we observed using HKY.
To address the mechanism(s) of resistance induced by vaccination with WGP or WGP-BSA, we examined the cytokine profile in serum and BAL after vaccination. bGlucans are immunomodulatory and have been reported to be primarily stimulatory, but also immunosuppressive in some instances (Soltanian et al., 2009) . Their mechanism of stimulation has been linked to various pattern recognition receptors such as dectin-1, TLR2/6 and CR3 among others (Soltanian et al., 2009; Huang et al., 2012) . Interactions with these receptors can result in increased production of proinflammatory cytokines including TNF-a, IL-1b, IL-6, IL-8 and IFN-c (Pelizon et al., 2005; Huang et al., 2009; Soltanian et al., 2009) . In addition, b-glucans have been reported to increase natural killer cell activity (Pelizon et al., 2005) and cause dendritic cell cytokine release dependent on dendritic cell stimulation with particular Toll-like receptor agonists (Huang et al., 2009) . Overall, our results are concordant in that the cytokines in the serum related to the innate immune response were present in higher concentrations in mice vaccinated with either preparation. Notably, granulocyte-CSF, granulocyte macrophage-CSF, TNF-a, MCP-1, MIP-1a, IL-6 and IFN-c were present in the sera of mice given WGP or WGP-BSA, indicative of a proinflammatory innate response. However, fewer of these were present in the BAL samples from vaccinated mice, particularly IFN-c and TNF-a. As our infection challenge route was systemic, the serum profile of cytokines would be more relevant.
With respect to cytokines related to an adaptive immune response, IL-10 and IL-17 were in higher concentrations in the WGP-BSA-vaccinated mice; IL-10 was not upregulated in the WGP-vaccinated mice. Both of these cytokines are related to an adaptive immune response, IL-10 to Th2 response and IL-17A to Th17 response. Th17 cells have been reported necessary for antifungal vaccine immunity (Wuthrich et al., 2003) and IL-17-producing CD8 + T cells (Tc17) have been shown necessary for antifungal immunity (Nanjappa et al., 2012) . Furthermore, those authors found that IL-6 is necessary for Tc17 differentiation and immunity, and we also found higher concentrations of IL-6 in the serum. Thus, we infer the vaccination with WGP or WGP-BSA induces an adaptive immune response. However, we cannot exclude the possibility that a priming of the innate response also plays a role in the induced protection. Previous studies have used a laminarindiphtheria toxoid conjugate as a vaccine and attributed the protection induced against Candida and Aspergillus infections in their models to be mediated by anti-b-glucan antibodies, and further demonstrated protection in naive mice with passive transfer of serum from vaccinated mice (Torosantucci et al., 2005 (Torosantucci et al., , 2009 ). In the present study, however, it appears that vaccination with WGP or WGP-BSA induced primarily a cell-mediated immune response, without inducing anti-b-glucan antibodies. This is suggestive of a different mechanism of protection from that reported with the laminarin-diphtheria toxoid conjugate (Torosantucci et al., 2005 (Torosantucci et al., , 2009 ).
How a b-glucan-based vaccine against aspergillosis would be used clinically is a relevant question. There are some groups at risk of aspergillosis who could be vaccinated when they are not immunosuppressed, or minimally. These groups would include: chronic granulomatous disease patients, transplant candidates prior to transplantation, leukaemics after successful induction therapy, bone marrow transplant patients prior to or after initial engraftment, patients with solid tumours at diagnosis or after initial therapy, and patients with rheumatologic or inflammatory bowel disease before heavy immunosuppressive therapy is initiated. Overall, the results of our studies support the potential of particulate b-glucans, either alone or conjugated, as vaccines against aspergillosis. The particulate preparations showed dose-responsive efficacy in the induction of protection, whereas lower molecular mass soluble bglucans were ineffective even when conjugated to BSA. It should be noted that we achieved protection without the use of an adjuvant and it is possible that the use of an adjuvant might allow for equivalent protection with smaller doses of the vaccine preparation. In preliminary work, we have found the WGP and WGP-BSA vaccine preparations also protect against experimental coccidioidomycosis . Future studies using specific proteins derived from Aspergillus are needed to further evaluate the potential of using a b-glucan-protein conjugate as an antifungal vaccine. These studies could entail the use of single proteins or preparations of multiple proteins to enhance the immune response to the organism, similar to what has been recently reported in studies of Coccidioides, which used three separate proteins (Hurtgen et al., 2012) . Additionally, multivalent preparations could be studied for cross protection against several fungal infections.
